First and foremost is the question of how to determine when the overall quality of evidence is adequate to demonstrate medical necessity for individual technologies and services.
Annu Rev Med — Iversen T, Luras H. We believe that lack of guidance on what is the most efficient way to reduce medical errors and improve the quality of health-care limits the scale-up of health system improvement interventions. Students will be asked to record a video on their own on a topic that will be assigned to them.
Many public and private payers have taken a very different approach over the last several years, investing considerable resources to make the medical policy process more scientific and transparent.
Only at the level of these individual decisions, it is argued, can all the subtle variations in clinical presentation and social context be thoroughly understood and factored into determinations about what is the best medically necessary care for the patient.
Herbst, C. Cost-effectiveness of two interventions for the prevention of postpartum hemorrhage in Senegal.
Interventions, such as antihypertensive and antiplatelet medications, are generally established as sufficiently cost-effective to reduce the risk of IHD and stroke.
One possible solution is to measure the process indicators as is feasible but then use epidemiological modeling to relate those process measures to tangible health outcomes using the best available evidence of the link between the process and ultimate outcomes.
For illustration, we discuss a cost-effectiveness analysis of the use of uterotonics during the third stage of labor to reduce the risk of post-partum hemorrhage PPH in Senegal as an example of a simple, well-defined individual medical intervention that has a single basic intended effect 18 in contrast to the cost-effectiveness analysis of a HSII to improve compliance with essential obstetric and newborn care including the use of uterotonics in the third stage of labor in Niger